Donor treatment with the lazeroid U74389G reduces ischemia-reperfusion injury in a rat lung transplant model

Bernard Hausen, Peter Mueller, Marcus Bahra, Raj Ranisamooj, Randall E. Morris, Charles W. Hewitt

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background. Antioxidant treatment with lazeroids has proven beneficial for the amelioration of reperfusion injury in experimental lung transplantation. This study compares the effect of donor versus recipient treatment on immediate postoperative graft function. Methods. A model of acute double-lung transplantation in rats was used to assess graft function. Transplanted controls after 2 (group I) and 16 hours of ischemia (group II) were compared to a recipient (group III; 16-hour ischemia) and a donor treatment group (group IV; 16-hour ischemia) using the lazeroid U74389G (6 mg/kg). Serial assessment of alveolar-arterial oxygen difference, dynamic lung compliance, airway and pulmonary vascular resistance was obtained during a 2-hour reperfusion period. Final analysis included survival, weight gain, and histologic examination. Results. Graft function was significantly better after 2 hours of ischemia than in any of the three 16-hour ischemia groups (IL III, IV). After 16 hours of ischemia, donor treatment provided superior graft function with respect to dynamic lung compliance, airway resistance, and alveolar-arterial oxygen difference when compared with groups II and III. The pulmonary vascular resistance was significantly higher in group III when compared with groups II and IV. Graft weight increase reflecting edema was highest in groups III (104%) and II (98%). Conclusions. After prolonged ischemia only donor treatment with the lazeroid U74389G was able to significantly reduce ischemia-reperfusion-related graft dysfunction.

Original languageEnglish (US)
Pages (from-to)814-820
Number of pages7
JournalAnnals of Thoracic Surgery
Volume64
Issue number3
DOIs
StatePublished - Sep 1997
Externally publishedYes

Fingerprint

Reperfusion Injury
Ischemia
Transplants
Lung
Lung Compliance
Lung Transplantation
Vascular Resistance
Reperfusion
Oxygen
Airway Resistance
Survival Analysis
Weight Gain
Edema
Antioxidants
Weights and Measures

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Donor treatment with the lazeroid U74389G reduces ischemia-reperfusion injury in a rat lung transplant model. / Hausen, Bernard; Mueller, Peter; Bahra, Marcus; Ranisamooj, Raj; Morris, Randall E.; Hewitt, Charles W.

In: Annals of Thoracic Surgery, Vol. 64, No. 3, 09.1997, p. 814-820.

Research output: Contribution to journalArticle

Hausen, Bernard ; Mueller, Peter ; Bahra, Marcus ; Ranisamooj, Raj ; Morris, Randall E. ; Hewitt, Charles W. / Donor treatment with the lazeroid U74389G reduces ischemia-reperfusion injury in a rat lung transplant model. In: Annals of Thoracic Surgery. 1997 ; Vol. 64, No. 3. pp. 814-820.
@article{9037f51c0e6e42c1b1d21c9f5ffdedf7,
title = "Donor treatment with the lazeroid U74389G reduces ischemia-reperfusion injury in a rat lung transplant model",
abstract = "Background. Antioxidant treatment with lazeroids has proven beneficial for the amelioration of reperfusion injury in experimental lung transplantation. This study compares the effect of donor versus recipient treatment on immediate postoperative graft function. Methods. A model of acute double-lung transplantation in rats was used to assess graft function. Transplanted controls after 2 (group I) and 16 hours of ischemia (group II) were compared to a recipient (group III; 16-hour ischemia) and a donor treatment group (group IV; 16-hour ischemia) using the lazeroid U74389G (6 mg/kg). Serial assessment of alveolar-arterial oxygen difference, dynamic lung compliance, airway and pulmonary vascular resistance was obtained during a 2-hour reperfusion period. Final analysis included survival, weight gain, and histologic examination. Results. Graft function was significantly better after 2 hours of ischemia than in any of the three 16-hour ischemia groups (IL III, IV). After 16 hours of ischemia, donor treatment provided superior graft function with respect to dynamic lung compliance, airway resistance, and alveolar-arterial oxygen difference when compared with groups II and III. The pulmonary vascular resistance was significantly higher in group III when compared with groups II and IV. Graft weight increase reflecting edema was highest in groups III (104{\%}) and II (98{\%}). Conclusions. After prolonged ischemia only donor treatment with the lazeroid U74389G was able to significantly reduce ischemia-reperfusion-related graft dysfunction.",
author = "Bernard Hausen and Peter Mueller and Marcus Bahra and Raj Ranisamooj and Morris, {Randall E.} and Hewitt, {Charles W.}",
year = "1997",
month = "9",
doi = "10.1016/S0003-4975(97)00525-0",
language = "English (US)",
volume = "64",
pages = "814--820",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - Donor treatment with the lazeroid U74389G reduces ischemia-reperfusion injury in a rat lung transplant model

AU - Hausen, Bernard

AU - Mueller, Peter

AU - Bahra, Marcus

AU - Ranisamooj, Raj

AU - Morris, Randall E.

AU - Hewitt, Charles W.

PY - 1997/9

Y1 - 1997/9

N2 - Background. Antioxidant treatment with lazeroids has proven beneficial for the amelioration of reperfusion injury in experimental lung transplantation. This study compares the effect of donor versus recipient treatment on immediate postoperative graft function. Methods. A model of acute double-lung transplantation in rats was used to assess graft function. Transplanted controls after 2 (group I) and 16 hours of ischemia (group II) were compared to a recipient (group III; 16-hour ischemia) and a donor treatment group (group IV; 16-hour ischemia) using the lazeroid U74389G (6 mg/kg). Serial assessment of alveolar-arterial oxygen difference, dynamic lung compliance, airway and pulmonary vascular resistance was obtained during a 2-hour reperfusion period. Final analysis included survival, weight gain, and histologic examination. Results. Graft function was significantly better after 2 hours of ischemia than in any of the three 16-hour ischemia groups (IL III, IV). After 16 hours of ischemia, donor treatment provided superior graft function with respect to dynamic lung compliance, airway resistance, and alveolar-arterial oxygen difference when compared with groups II and III. The pulmonary vascular resistance was significantly higher in group III when compared with groups II and IV. Graft weight increase reflecting edema was highest in groups III (104%) and II (98%). Conclusions. After prolonged ischemia only donor treatment with the lazeroid U74389G was able to significantly reduce ischemia-reperfusion-related graft dysfunction.

AB - Background. Antioxidant treatment with lazeroids has proven beneficial for the amelioration of reperfusion injury in experimental lung transplantation. This study compares the effect of donor versus recipient treatment on immediate postoperative graft function. Methods. A model of acute double-lung transplantation in rats was used to assess graft function. Transplanted controls after 2 (group I) and 16 hours of ischemia (group II) were compared to a recipient (group III; 16-hour ischemia) and a donor treatment group (group IV; 16-hour ischemia) using the lazeroid U74389G (6 mg/kg). Serial assessment of alveolar-arterial oxygen difference, dynamic lung compliance, airway and pulmonary vascular resistance was obtained during a 2-hour reperfusion period. Final analysis included survival, weight gain, and histologic examination. Results. Graft function was significantly better after 2 hours of ischemia than in any of the three 16-hour ischemia groups (IL III, IV). After 16 hours of ischemia, donor treatment provided superior graft function with respect to dynamic lung compliance, airway resistance, and alveolar-arterial oxygen difference when compared with groups II and III. The pulmonary vascular resistance was significantly higher in group III when compared with groups II and IV. Graft weight increase reflecting edema was highest in groups III (104%) and II (98%). Conclusions. After prolonged ischemia only donor treatment with the lazeroid U74389G was able to significantly reduce ischemia-reperfusion-related graft dysfunction.

UR - http://www.scopus.com/inward/record.url?scp=0030846232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030846232&partnerID=8YFLogxK

U2 - 10.1016/S0003-4975(97)00525-0

DO - 10.1016/S0003-4975(97)00525-0

M3 - Article

C2 - 9307479

AN - SCOPUS:0030846232

VL - 64

SP - 814

EP - 820

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 3

ER -